Lupin's Generic Entresto Approved by USFDA, Set to Rival Novartis' Bestseller
Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sacubitril and Valsartan Tablets. This comes amid an ongoing legal tussle between Novartis and generics manufacturers, including MSN Pharmaceuticals.
Announcing the approval, Lupin confirmed that its Abbreviated New Drug Application (ANDA) for Sacubitril and Valsartan Tablets has been cleared by the FDA. These tablets are indicated for reducing the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure and reduced ejection fraction, as well as for treating symptomatic heart failure in pediatric patients aged one year and older.
Also Read: Lupin receives USFDA approval for heart failure drug
Entresto remains one of Novartis' top-selling drugs, according to a recent media report in ET, generating over USD 6 billion in the U.S. drug market in 2023. However, the Swiss pharmaceutical giant has been aggressively defending its patent, leading to multiple lawsuits against generics manufacturers.
In 2022, Novartis sued MSN Pharmaceuticals and other companies in a Delaware federal court, alleging patent infringement over their generic versions of Entresto. It also took legal action against the FDA, arguing that the agency’s approval of MSN’s generic was “unlawful.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.